Likewise, future analysis of predictors of therapy response using other biological drugs with different mechanism of action (Anti-CD20, Anti-IL6, JAK-inhibitors etc.)will be also required for the development of a wide approach of personalized medicine in RA patients in which all the available drugs are included. The gene discussed is IL6; the disease is rheumatoid arthritis.